RxDoctor Payments Data

Michael Wertheim, MD

Hematology & Oncology · Fort Myers, FLNPI 1982643474

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $68,828 of the $106,242 with a category attached, or 64.8%. It is spread thinly across 60 manufacturers, the largest accounting for just 22.6%. Reporting peaked in 2019 at $51,033 and has fallen 99.8% since, to $83 in 2025. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$106,242in general payments, 2019–2025

Across 955 payments — averaging $111.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$24K
  • Genentech USA, Inc.$9K
  • Takeda Pharmaceuticals U.S.A., Inc.$9K
  • Seagen Inc.$9K
  • Amgen$9K
  • E.r. Squibb & Sons, L.L.C.$8K
  • plus $38K from 54 others
$676,832in research payments, 2019–2025

Across 212 payments — averaging $3192.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • EMD Serono, Inc.$445K
  • Array Biopharma Inc$120K
  • E.r. Squibb & Sons, L.L.C.$69K
  • Janssen Research & Development, LLC$29K
  • Incyte Corporation$13K
  • Bayer$661

What the payments were for

  • Consulting fees$19,32218%
  • Speaking & faculty fees$68,82865%
  • Travel & lodging$1,6032%
  • Food & beverage$14,63514%
  • Education$5731%
  • Other$1,2801%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)93$24,024
Genentech USA, Inc.52$9,062
Takeda Pharmaceuticals U.S.A., Inc.24$8,918
Seagen Inc.34$8,890
Amgen52$8,870
E.r. Squibb & Sons, L.L.C.38$8,495
Bristol Myers Squibb47$5,611
Mirati Therapeutics, Inc.20$5,312
Array Biopharma Inc19$4,602
Incyte Corporation20$4,310
Astellas Pharma US Inc17$2,900
AbbVie31$1,781
Novartis38$1,684
Daiichi Sankyo Inc.16$1,528
Pfizer129$1,494
Beigene USA, Inc.4$1,427
Sanofi52$1,245
Merck49$752
Johnson & Johnson22$482
GSK17$457
Beigene, Ltd.1$450
Janssen Scientific Affairs, LLC1$350
Lilly USA, LLC20$330
Eisai Inc.13$243
Bayer12$216
Novocure GmbH1$200
Karyopharm Therapeutics Inc.8$180
Athenex Pharmaceutical Division, LLC1$175
Sobi, Inc10$174
Dova Pharmaceuticals11$172
Jazz Pharmaceuticals Inc.9$154
Puma Biotechnology, Inc.8$150
Gilead(2 entities)10$148
Exelixis Inc.7$131
Regeneron Healthcare Solutions, Inc.6$121
Comsort, Inc1$100
Coherus Oncology, Inc.4$89
Boehringer Ingelheim5$85
Ipsen Biopharmaceuticals, Inc4$72
Grifols USA, LLC3$65
AMAG Pharmaceuticals, Inc.4$63
G1 Therapeutics, Inc.3$61
Tolmar Pharmaceuticals, Inc.4$58
EMD Serono, Inc.3$54
AVEO Pharmaceuticals, Inc.2$51
Taiho Oncology, Inc.3$51
Blueprint Medicines Corporation2$49
Tesaro, Inc.3$47
Agios Pharmaceuticals, Inc.3$44
Morphosys, US Inc.2$44
Pharmacyclics LLC, An Abbvie Company2$38
Sun Pharmaceutical Industries Inc.2$37
Aurobindo Pharma USA, Inc.2$29
Teva Pharmaceuticals USA, Inc.1$19
Foundation Medicine, Inc.1$19
Cumberland Pharmaceuticals, Inc.1$18
Mylan Institutional Inc.1$17
Acceleron Pharma, Inc.1$15
Kyowa Kirin, Inc.1$15
Tolmar, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$106,242 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida →

Medicare billing

Part B allowed, 2024
$84,293
Medicare patients
109
Services billed
4,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydroxyurea11$313

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Fort Myers

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →